Skip to content

3D Ultrasound-guided Labor Epidural Analgesia in the Morbid Obese Parturient

3D Ultrasound-guided Labor Epidural Analgesia in the Morbid Obese Parturient: A Randomized Control Trial

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03405311
Enrollment
40
Registered
2018-01-23
Start date
2018-02-20
Completion date
2024-01-11
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Morbid, Pregnancy, Pain

Keywords

Labor analgesia, Ultrasound, Obesity, Morbid, Pregnancy, Labor Epidural Analgesia

Brief summary

This study will be a randomized control study, with the objective to evaluate epidural analgesia success rates between the two methods (Blind Approach versus Accuro Device).

Detailed description

Worldwide obesity has become an epidemic. The obstetrical population is no exception. This made more challenging for anesthesiologists on labor and delivery units to administer epidural analgesia. According to the World Health Organization, more than 30% of U.S. adults are obese with a body mass index (BMI; in kg/m2) ≥ 30. Recent data has shown that increased BMI has been associated with increased neuraxial analgesic failure and difficulty with prolonged epidural placement time. The 'Blind approach' is the current standard of care in administering neuraxial anesthesia. The physician palpates the patient's spinal bony landmarks; the needle is placed in relation to identified landmarks and inserted until loss of resistance is felt. In the obese population, the success rates are as low as 68%. Recently the FDA has approved a handheld device "The Accuro" as an adjunct for neuraxial analgesia (Rivanna Medical, LLC). It consists of a three-dimensional ultrasound device. By utilizing sound waves it constructs three-dimensional images of the spinal column, allowing the physician to better see the spine in order to perform spinal/epidural anesthesia. Hypothesize that this device will enable clinicians to assess epidural spaces for epidural needle placement compared with the traditional Blind approach in the morbidly obese parturient. This study will be a randomized control study, with the objective to evaluate epidural analgesia success rates between the two methods (Blind Approach versus Accuro Device). Also, will determine if ultrasound based landmarks would reduce the needle tract and thereby reduced the amount of post-procedure pain at the insertion site in the peripartum period by using the algometer.

Interventions

DEVICERivanna Accuro 3D Ultrasound Device

The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device

The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode

Sponsors

The University of Texas Medical Branch, Galveston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists physical status class I, II, or III. * Term pregnancy. * Requesting epidural analgesia for anticipated vaginal delivery. * BMI\>or = 40.

Exclusion criteria

* Contraindication for epidural analgesia * Inability to adequately understand the consent form. * Incarcerated patients. * Patients with known spinal deformities. * Allergies to ultrasound gel. * Allergies to local anesthetics

Design outcomes

Primary

MeasureTime frameDescription
Number of Needle Insertion Attempts Calculated Across All ParticipantsBeginning of needle insertion till catheter placement-15 minutesAn epidural insertion attempt will be defined as advancement of the needle in an effort to enter the epidural space; a needle requiring withdrawal for redirection or reinsertion through the skin/another skin puncture will be counted as an additional attempt.
Number of Participants With Successful Epidural Catheter PlacementsWithin first 90 minutes following catheter placementNumber of Participants With Successful Epidural Catheter Placements.
Number of Needle Insertion Redirections Calculated Across All ParticipantsBeginning of needle insertion till catheter placement-15 minutesAn epidural insertion attempt will be defined as advancement of the needle in an effort to enter the epidural space; a needle requiring withdrawal for redirection or reinsertion through the skin/another skin puncture will be counted as an additional attempt.

Secondary

MeasureTime frameDescription
Procedural Difficulty Rated by the Performing Anesthesiologist on a 10-point Likert ScaleBeginning of needle insertion till catheter placement-15 minutesProcedural difficulty will be rated by the performing anesthesiologist on a 10-point Likert scale from one (easy) to ten (extremely difficult).
Needle DepthBeginning of needle insertion till catheter placement-15 minutesWe will also record thouy needle depth from skin and measured depth by ultrasound.
Pressure Pain ThresholdsBefore epidural placementPressure pain thresholds will be obtained immediately prior to the epidural placement using the pressure pain device.
Number of Complications Recorded Calculated Across All ParticipantsWithin 30 days of admissionThe number of complications related to the epidural recorded within 30 days of admission.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRovnat Babazade, MD

The University of Texas Medical Branch

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
40 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
Sex: Female, Male
Female
20 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 20
other
Total, other adverse events
0 / 200 / 20
serious
Total, serious adverse events
0 / 200 / 20

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026